Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shahnaz Shahinfar

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Clinical and Experimental Nephrology|September 30, 2006
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL studyKiyoshi Kurokawa, Juliana C N Chan, Mark E Cooper, et al.
Kidney International. Supplement|November 2, 2002
Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL StudyShahnaz Shahinfar, Tania Z Dickson, Tultul Ahmed, et al.
Kidney International. Supplement|November 2, 2002
Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European UnionWilliam C Gerth, Giuseppi Remuzzi, GianCarlo Viberti, et al.
Pediatric Nephrology (Berlin, Germany)|December 5, 2012
Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndromeNicholas J A Webb, Shahnaz Shahinfar, Thomas G Wells, et al.
Journal of Clinical Pharmacology|June 24, 2003
Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairmentTania Z Dickson, JoAnn Zagrobelny, Charles C Lin, et al.
Clinical Therapeutics|December 13, 2006
A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertensionGilbert W Gleim, Joseph Rubino, Hongyan Zhang, et al.
Journal of the American Society of Nephrology : JASN|July 17, 2010
Comparison of different measures of urinary protein excretion for prediction of renal eventsHiddo J Lambers Heerspink, Ron T Gansevoort, Barry M Brenner, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 3, 2011
Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trialNicholas J A Webb, Chun Lam, Shahnaz Shahinfar, et al.
Kidney International|June 29, 2012
Losartan and enalapril are comparable in reducing proteinuria in childrenNicholas J A Webb, Shahnaz Shahinfar, Thomas G Wells, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 22, 2010
Randomized, double-blind, controlled study of losartan in children with proteinuriaNicholas J A Webb, Chun Lam, Tom Loeys, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Clinical and Experimental Nephrology|September 30, 2006
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL studyKiyoshi Kurokawa, Juliana C N Chan, Mark E Cooper, et al.
Kidney International. Supplement|November 2, 2002
Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL StudyShahnaz Shahinfar, Tania Z Dickson, Tultul Ahmed, et al.
Kidney International. Supplement|November 2, 2002
Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European UnionWilliam C Gerth, Giuseppi Remuzzi, GianCarlo Viberti, et al.
Pediatric Nephrology (Berlin, Germany)|December 5, 2012
Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndromeNicholas J A Webb, Shahnaz Shahinfar, Thomas G Wells, et al.
Journal of Clinical Pharmacology|June 24, 2003
Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairmentTania Z Dickson, JoAnn Zagrobelny, Charles C Lin, et al.
Clinical Therapeutics|December 13, 2006
A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertensionGilbert W Gleim, Joseph Rubino, Hongyan Zhang, et al.
Journal of the American Society of Nephrology : JASN|July 17, 2010
Comparison of different measures of urinary protein excretion for prediction of renal eventsHiddo J Lambers Heerspink, Ron T Gansevoort, Barry M Brenner, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 3, 2011
Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trialNicholas J A Webb, Chun Lam, Shahnaz Shahinfar, et al.
Kidney International|June 29, 2012
Losartan and enalapril are comparable in reducing proteinuria in childrenNicholas J A Webb, Shahnaz Shahinfar, Thomas G Wells, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 22, 2010
Randomized, double-blind, controlled study of losartan in children with proteinuriaNicholas J A Webb, Chun Lam, Tom Loeys, et al.
Pageof 5